Skip to content
TrialScanner

NCT04123626

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

Phase 1/Phase 2Active, not recruitingPRQRLead

Registry record

Lead sponsor
ProQR Therapeutics
Conditions
Autosomal Dominant Retinitis Pigmentosa; Eye Diseases; Eye Diseases, Hereditary; Retinal Dystrophies; Retinal Disease
Primary completion
Jun 7, 2022Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT04123626 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04123626: A Study to Evaluate the... | TrialScanner